A detailed history of Victory Capital Management Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 144,280 shares of IOVA stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
144,280
Previous 28,893 399.36%
Holding current value
$1.07 Million
Previous $231,000 486.15%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$7.28 - $11.9 $840,017 - $1.37 Million
115,387 Added 399.36%
144,280 $1.35 Million
Q2 2024

Aug 05, 2024

SELL
$7.78 - $14.19 $497 - $908
-64 Reduced 0.22%
28,893 $231,000
Q1 2024

May 03, 2024

BUY
$7.59 - $17.47 $15,453 - $35,568
2,036 Added 7.56%
28,957 $429,000
Q4 2023

Feb 05, 2024

BUY
$3.3 - $8.89 $14,265 - $38,431
4,323 Added 19.13%
26,921 $218,000
Q3 2023

Nov 06, 2023

BUY
$4.44 - $8.79 $17,480 - $34,606
3,937 Added 21.1%
22,598 $102,000
Q2 2023

Jul 27, 2023

SELL
$5.36 - $9.06 $2,326 - $3,932
-434 Reduced 2.27%
18,661 $131,000
Q1 2023

May 02, 2023

SELL
$5.53 - $8.22 $131,448 - $195,389
-23,770 Reduced 55.45%
19,095 $116,000
Q4 2022

Feb 09, 2023

SELL
$5.62 - $10.0 $561,421 - $998,970
-99,897 Reduced 69.97%
42,865 $273,000
Q3 2022

Nov 02, 2022

SELL
$9.53 - $13.11 $401,451 - $552,258
-42,125 Reduced 22.78%
142,762 $1.37 Million
Q2 2022

Aug 01, 2022

SELL
$6.38 - $18.33 $245,311 - $704,788
-38,450 Reduced 17.22%
184,887 $2.04 Million
Q1 2022

May 04, 2022

SELL
$12.38 - $19.1 $859,667 - $1.33 Million
-69,440 Reduced 23.72%
223,337 $3.68 Million
Q4 2021

Feb 07, 2022

SELL
$16.55 - $27.63 $279,281 - $466,256
-16,875 Reduced 5.45%
292,777 $5.59 Million
Q3 2021

Nov 02, 2021

SELL
$20.35 - $26.63 $1.58 Million - $2.06 Million
-77,430 Reduced 20.0%
309,652 $7.64 Million
Q2 2021

Aug 03, 2021

SELL
$16.33 - $33.07 $24.7 Million - $50 Million
-1,513,108 Reduced 79.63%
387,082 $10.1 Million
Q1 2021

May 04, 2021

SELL
$28.67 - $52.59 $3.58 Million - $6.56 Million
-124,764 Reduced 6.16%
1,900,190 $60.2 Million
Q4 2020

Feb 01, 2021

SELL
$28.04 - $50.26 $1.52 Million - $2.73 Million
-54,284 Reduced 2.61%
2,024,954 $94 Million
Q3 2020

Nov 09, 2020

SELL
$27.75 - $36.3 $5.02 Million - $6.57 Million
-181,000 Reduced 8.01%
2,079,238 $68.4 Million
Q2 2020

Aug 07, 2020

BUY
$27.21 - $41.0 $7.17 Million - $10.8 Million
263,368 Added 13.19%
2,260,238 $62 Million
Q1 2020

May 04, 2020

SELL
$19.54 - $38.85 $8.82 Million - $17.5 Million
-451,317 Reduced 18.43%
1,996,870 $59.8 Million
Q4 2019

Feb 06, 2020

SELL
$17.95 - $29.41 $303,929 - $497,970
-16,932 Reduced 0.69%
2,448,187 $67.8 Million
Q4 2019

Feb 04, 2020

BUY
$17.95 - $29.41 $2.62 Million - $4.29 Million
145,951 Added 6.29%
2,465,119 $53.6 Million
Q3 2019

Nov 12, 2019

BUY
$17.99 - $26.0 $5.6 Million - $8.1 Million
311,425 Added 15.51%
2,319,168 $42.2 Million
Q2 2019

Aug 15, 2019

SELL
$9.78 - $24.52 $4.56 Million - $11.4 Million
-466,394 Reduced 18.85%
2,007,743 $49.2 Million
Q1 2019

May 03, 2019

SELL
$8.41 - $11.26 $4.61 Million - $6.17 Million
-547,790 Reduced 18.13%
2,474,137 $23.5 Million
Q4 2018

Feb 05, 2019

BUY
$7.51 - $11.93 $4.44 Million - $7.05 Million
591,270 Added 24.33%
3,021,927 $26.7 Million
Q3 2018

Nov 01, 2018

BUY
$11.25 - $17.7 $971,752 - $1.53 Million
86,378 Added 3.68%
2,430,657 $27.3 Million
Q2 2018

Aug 02, 2018

BUY
$12.45 - $16.95 $731,811 - $996,321
58,780 Added 2.57%
2,344,279 $30 Million
Q1 2018

May 04, 2018

BUY
$8.1 - $19.5 $1.49 Million - $3.59 Million
184,336 Added 8.77%
2,285,499 $38.6 Million
Q4 2017

Feb 01, 2018

SELL
$6.65 - $9.25 $3.57 Million - $4.97 Million
-537,160 Reduced 20.36%
2,101,163 $16.8 Million
Q3 2017

Oct 27, 2017

BUY
$4.45 - $8.55 $228,952 - $439,897
51,450 Added 1.99%
2,638,323 $20.4 Million
Q2 2017

Aug 07, 2017

BUY
N/A
2,586,873
2,586,873 $19 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.17B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.